#HorizonEU

THE EU RESEARCH & INNOVATION PROGRAMME

2021 – 2027

InfoDay Nazionale
24.10.2023

Bianca BALUTA
Programme officer

DG CNECT - eHealth, Wellbeing and Ageing
European Commission

Research and Innovation

Disclaimer: information not legally binding

HEALTH

CLUSTER 1 - Work Programme 2023-2024 (2024 calls)

LE OPPORTUNITÀ 2024 NEL CLUSTER 1 - HEALTH

24 October 2023

DISCLAIMER: THE VIEWS EXPRESSED ARE PURELY THOSE OF THE WRITER AND MAY NOT UNDER ANY CIRCUMSTANCES BE REGARDED AS STATING AN OFFICIAL POSITION OF THE EUROPEAN COMMISSION. THESE SLIDES ARE COPYRIGHT OF THE EUROPEAN COMMISSION.

European Commission

Horizon Europe – Cluster 1 Health Work Programme 2023-2024

Strategic Plan 2021-24 → 6 Expected Impacts = 6 "Destinations":

Destination 1: Staying healthy in a rapidly changing society

Destination 2: Living and working in a health-promoting environment

Destination 3: Tackling diseases & reducing disease burden

Destination 4: Ensuring access to innovative, sustainable & high-quality healthcare

Destination 5: Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

Destination 6: Maintaining an innovative, sustainable & globally competitive health industry

European Commission

Disclaimer: information not legally binding

Horizon Europe – Cluster 1 Health Work Programme 2023-2024

Topics (Calls)

Focus on outcomes contributing to the impacts specified per Destination

Project proposals should:

- make a **clear case** (*value proposition*)
- supported by a **convincing trajectory** (*pathway to impact*) for the project proposal to deliver the **output**, promote the **outcome** described in the topic, and contribute to the **impact** expected under that destination.

European Commission

Disclaimer: information not legally binding

Horizon Europe – Cluster 1 Health

Timeline for Work Programme **2024** calls for proposals (single stage):

- Opening of calls: 26 October 2023
- Closure of calls (deadline): **11 April 2024**

*Except “HORIZON-HLTH-2024-DISEASE-09-01: European Partnership: One Health Anti Microbial Resistance **(25 April 2024 – 25 September 2024)**

Work Programme 2023-24 document:
https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-4-health_horizon-2023-2024_en.pdf

Funding & Tender opportunities portal:
https://ec.europa.eu/info/funding-tenders/opportunities/portal/

Disclaimer: information not legally binding

European Commission

Destination 3: Tackling diseases and reducing disease burden - 3 topics in 2024 (1 RIA, 1 CSA and 1 COFUND)

- HORIZON-HLTH-2024-DISEASE-08-12**: Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness**
- **Closure: 11.04.2024**
- Instrument: CSA
- Budget: 2M€
- Project size: 2M€

- HORIZON-HLTH-2024-DISEASE-08-20: **Pandemic preparedness and response: Host pathogen interactions of infectious diseases with epidemic potential**
- **Closure: 11.04.2024**
- Instrument: RIA
- Budget: 50M€
- Project size: 7-8M€

- **HORIZON-HLTH-2024-DISEASE-09-01: **European Partnership: One Health Anti-Microbial Resistance***
- ***Closure: 25.09.2024***
- *Instrument: COFUND*
- *Budget: 100M€*
- *Project size: 100M€*

European Commission

Disclaimer: information not legally binding

Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness

Expected outcomes (address **all of the following** elements):

- Research funders, policymakers and the research community maintain a **consolidated research and innovation framework for the European partnership for pandemic preparedness**, including the Partnership's objectives, governance and ways of working/operationalisation;
- Research funders, policymakers and the research community are **aligned towards common objectives and have a common understanding** of the long-term Strategic Research and Innovation Agenda for the Partnership;
- European research funders are supported by a **dynamic and efficient secretariat** in their coordination efforts for pandemic preparedness research;
- Healthcare providers, European and international stakeholders engage with the appropriate partners through the research and innovation framework for the partnership.

European Commission

Disclaimer: information not legally binding

Pandemic preparedness and response: Host pathogen interactions of infectious diseases with epidemic potential

Expected outcomes (address **all of the following** elements):

The scientific and clinical communities have:

- increased knowledge on viruses with epidemic potential and in particular a better understanding of pathogen–host interactions for **the targeted development of vaccines and inhibitors for the prevention of viral infection** and the viral transmission during pathogenesis.
- access to novel approaches for the **prevention and treatment for emerging and re-emerging infections** in the context of epidemic and pandemic preparedness.
- access to **experimental vaccine candidates and candidates that inhibit cellular uptake of viruses** against emerging or re-emerging viral infections for further clinical investigation.

European Commission

Disclaimer: information not legally binding

European Partnership: One Health Anti-Microbial Resistance

Expected outcomes (address **several of the following** elements):

- Health burden of diseases in the EU and worldwide is reduced through effective disease management;
- Premature mortality from non-communicable diseases is reduced by one third (by 2030), mental health and well-being is promoted, and the voluntary targets of the WHO Global Action Plan for the Prevention and Control of NCDs 2013-2020 are attained (by 2025);
- Health care systems benefit from strengthened research and innovation expertise, human capacities and know-how for combatting communicable and non-communicable diseases;
- Citizens benefit from reduced (cross-border) health threat of epidemics and AMR pathogens, in the EU and worldwide;
- Patients and citizens are knowledgeable of disease threats, involved and empowered to make and shape decisions for their health.

European Commission

Disclaimer: information not legally binding

Destination 5: Unlocking the full potential of new tools, technologies and digital solutions for a healthy society - 1 topic in 2024 (1 RIA)

- HORIZON-HLTH-2024-TOOL-11-02:
  Bio-printing of living cells for regenerative medicine

- **Closure: 11.04.2024**
- Instrument: RIA
- Budget: 25M€
- Project size: 6-8M€

European Commission

Disclaimer: information not legally binding

Bio-printing of living cells for regenerative medicine

Expected outcomes (address **several of the following** elements):

- Biomedical scientists will access entire **bio-printing units for regenerating human tissue**.
- **Availability of larger-scale bio-printed tissues** for biomedical research purposes to both industry and academia.
- Healthcare professionals acquire information on the safe and effective use of **advanced therapies**.
- Healthcare providers dispose of tools enabling them to treat conditions of unmet medical need.
- Individual patients will benefit from a **personalised approach** to their respective medical condition thanks to the bio-printed regenerative medicine solution.

European Commission

Disclaimer: information not legally binding

Destination 6: Maintaining an innovative, sustainable & globally competitive health industry – 2 topics in 2024 (1 RIA & 1 CSA

- HORIZON-HLTH-2024-IND-06-08: **Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)**

- **Closure: 11.04.2024**
- Instrument: RIA
- Budget: 10M€
- Project size: 8-10M€

- HORIZON-HLTH-2024-IND-06-09: **Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators**

- **Closure: 11.04.2024**
- Instrument: CSA
- Budget: 2M€
- Project size: 2M€

European Commission

Disclaimer: information not legally binding

Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)

Expected outcomes (address **all of the following** elements):

- Patients gain **faster access** to innovative, safe and well-performing medical devices;
- Regulators have **access to sound scientific resources** for clinical/performance evaluation guidance and development of common specifications as foreseen in Article 9 of the Medical Device Regulation (MDR);
- Notified bodies, by their direct participation to the production of documents, will have a **harmonised way of assessing the clinical evidence in the pre-market and post-market phases**;
- Health technology developers **gain insight on the evidence needed** to demonstrate that their devices meet MDR clinical requirements throughout their lifetime.

European Commission

Disclaimer: information not legally binding

Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators

(1) Expected outcomes (address **all of the following** elements):

European regulators:

- Gain state-of-the-art knowledge on different NAMs that are being proposed for the assessment of the safety and efficacy of chemicals and pharmaceuticals;
- Understand better the shortcomings of the current tools based on animal procedures for the assessment of chemicals and pharmaceuticals;
- Collaborate on a framework on how to assess the safety of chemicals based on NAM-data and how to classify the hazardous properties based on such data;
- Collaborate on a similar framework for assessment of safety and efficacy of pharmaceuticals based on NAM-data;

European Commission

Disclaimer: information not legally binding

Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators

(2) Expected outcomes (address **all of the following** elements):

- Citizens benefit from the supply and use of chemicals and pharmaceuticals that have been assessed through NAMs that are better predicting potential effects in humans than the current assessment methods;
- Industry has an improved competitive position with the availability of harmonised and standardised NAM-based assessment tools that are faster and more flexible;
- European Commission and Member States regulators are responding to the societal demand to move away from animal testing.

European Commission

Disclaimer: information not legally binding

More information

1. **Admissibility conditions**: described in Annex A and Annex E of the Horizon Europe WP General Annexes.

2**. Eligible countries**: described in Annex B of the WP General Annexes.

3. **Other eligibility conditions**: described in Annex B of the WP General Annexes.

4. **Financial and operational capacity and exclusion**: described in Annex C of the WP General Annexes.

5. **Evaluation and award**: award criteria, scoring and thresholds are described in Annex D of the WP General Annexes.

6. **Legal and financial set-up of the grants**: described in Annex G of the Work Programme General Annexes.

European Commission

Disclaimer: information not legally binding

Thank you!

#HorizonEU

http://ec.europa.eu/horizon-europe

© European Union 2021

Unless otherwise noted the reuse of this presentation is authorised under the CC BY 4.0 license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.
Image credits: © ivector #249868181, #251163013, #273480523, #241215668, #245719946, #251163053, #252508849, #241215668, #244690530, #222596698, #235536634, #263530636, #66009682, #273480523, #362422833; © petovarga #366009967; © shooarts # 121467308, 2020. Source: Stock.Adobe.com. Icons © Flaticon – all rights reserved.